|
Synonyms: M200
Compound class:
Antibody
Comment: Volociximab is a chimeric human IgG4 anti-integrin α5 subunit monoclonal antibody [5]. It blocks the interaction between α5β1 and fibronectin and inhibits the complex's functional activity [4], and was originally developed for anti-angiogenic, anti-tumour potential [1-2]. Volociximab does not cross-react with murine α5β1 so is unsuitable for use in standard xenograft models [2]. A rat anti-mouse function-blocking α5β1 designed for murine experiments has been reported (339.1, Kd 0.59 nM), and like volociximab it inhibits angiogenesis and slows tumour growth in vivo[3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Almokadem S, Belani CP. (2012)
Volociximab in cancer. Expert Opin Biol Ther, 12 (2): 251-7. [PMID:22192080] |
|
2. Bhaskar V, Fox M, Breinberg D, Wong MH, Wales PE, Rhodes S, DuBridge RB, Ramakrishnan V. (2008)
Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs, 26 (1): 7-12. [PMID:17786386] |
|
3. Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V. (2007)
A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med, 5: 61. [PMID:18042290] |
|
4. Ng CM, Bai S, Takimoto CH, Tang MT, Tolcher AW. (2010)
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients. Cancer Chemother Pharmacol, 65 (2): 207-17. [PMID:19468731] |
|
5. Ramakrishnan V, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, O'Hara C, Powers DB, Liu G, Grove J et al.. (2006)
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol, 5 (4): 273-86. [PMID:17024968] |
